PD-L1 has been extensively described as the membrane-bound ligand of PD-1. A recent study discovered a previously unknown role for PD-L1, which is able to bind DNA and thus govern different pathways linked to either evasion of immune surveillance or tumour microenvironment inflammation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
Cancer Cell International Open Access 16 September 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Baumeister, S. H., Freeman, G. J., Dranoff, G. & Sharpe, A. H. Annu. Rev. Immunol. 34, 539–573 (2016).
Li, X. et al. Nat. Rev. Clin. Oncol. 16, 425–441 (2019).
Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D. & López-Soto, A. Sci. Transl. Med. Rev. 10, eaat7807 (2018).
Azuma, T. et al. Blood 111, 3635–3643 (2008).
Chang, C. H. et al. Cell 162, 1229–1241 (2015).
Chen, N. et al. J. Thorac. Oncol. 10, 910–923 (2015).
Tu, X. et al. Mol. Cell 74, 1215–1226.e4 (2019).
Song, H. et al. Biochem. Biophys. Res. Commun. 404, 68–73 (2011).
Gao, Y. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-020-0562-4 (2020).
Yoo, C. B. & Jones, P. A. Nat. Rev. Drug Discov. 5, 37–50 (2006).
von Burstin, J. et al. Gastroenterology 137, 361–371 (2009).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Jaccard, A., Ho, PC. The hidden side of PD-L1. Nat Cell Biol 22, 1031–1032 (2020). https://doi.org/10.1038/s41556-020-0568-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41556-020-0568-y
This article is cited by
-
Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
Cancer Cell International (2023)